Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for refractory rheumatoid arthritis
NCT06215638Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of bortezomib in rheumatoid arthritis (RA), sponsored by Peking Union Medical College Hospital. Primary endpoint: American College of Rheumatology 20% improvement criteria at 12 weeks. Status: unknown.
02
Drugs
bortezomib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06215638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215638.